**
In a revealing turn of events, newly uncovered documents indicate that senior officials from the Trump administration met with Bayer’s CEO, Bill Anderson, to discuss litigation regarding the controversial glyphosate herbicide. This meeting, held on 17 June 2025, has ignited fierce debate over corporate influence in regulatory decisions, particularly as tens of thousands of Americans allege that glyphosate products, like Roundup, have caused them serious health issues, including cancer.
Meeting Details Exposed
The meeting at the Environmental Protection Agency (EPA) was attended by key figures, including Lee Zeldin, then EPA administrator, and two other Bayer executives. The agenda reportedly focused on legal strategies, specifically surrounding potential Supreme Court actions aimed at reducing Bayer’s liability related to glyphosate. The company is currently embroiled in lawsuits claiming it failed to adequately warn consumers of the cancer risks associated with its products—a situation that has already cost Bayer billions in settlements.
Bayer’s defence hinges on a legal argument suggesting that if the EPA does not mandate a cancer warning for glyphosate, the company should not be held accountable for failing to provide one. While one appellate court has sided with Bayer, numerous others, as well as the Biden administration’s solicitor general, have rejected this position. In stark contrast, the Trump administration has taken steps to bolster Bayer’s claims.
Administration’s Support for Bayer
Following the 17 June meeting, the Trump administration’s support for Bayer manifested in several significant actions. Notably, in a 1 December filing, the solicitor general called for the Supreme Court to hear Bayer’s case, a request that was subsequently granted. This led to a scheduled hearing on 27 April 2026. Furthermore, the White House invoked the Defense Production Act in February 2026 to safeguard glyphosate production, effectively providing immunity for Bayer and similar companies.
In a March 2026 amicus brief, the Trump administration officially lent its backing to Bayer’s case, a move that has drawn scrutiny from environmental advocates and legal experts alike.
Corporate Influence Under Scrutiny
Critics of the meeting point to the alarming implications of such high-level discussions between regulatory officials and corporate leaders. Nathan Donley, an environmental health scientist with the Center for Biological Diversity, expressed concerns that the meeting exemplifies a troubling trend where regulatory decisions appear to favour corporate interests over public health. “When the CEO of one of the largest companies in the world meets with political appointees in a regulatory office, it highlights the extent of corporate influence over decisions that affect the well-being of all Americans,” he stated.
Legal experts have also voiced their alarm. Whitney Di Bona, an attorney focused on consumer safety, questioned whether the EPA has afforded similar opportunities for dialogue to the many individuals claiming health consequences from glyphosate usage. Naomi Oreskes, a Harvard professor who examines corporate influence on regulation, noted that the meeting underscores a pattern where industry leaders have privileged access to government officials, while the public remains largely excluded from the conversation.
Community Voices and Advocacy
Grassroots organisations have long voiced their concerns about chemical companies’ sway over regulatory bodies. Zen Honeycutt, founder of Moms Across America, remarked that coercion by chemical companies in regulatory processes is an ongoing issue. Despite multiple meetings with EPA leadership, her organisation has seen little progress on calls to restrict or ban harmful pesticides.
Bayer, for its part, has defended the meeting as a standard component of the regulatory process, asserting that it maintains transparency regarding its position on glyphosate. However, the fallout from this incident raises critical questions about the integrity of regulatory practices and the extent to which corporate interests can shape the regulatory landscape.
Why it Matters
The implications of this meeting extend beyond the courtroom, touching on broader issues of public health, corporate accountability, and governmental transparency. As the legal battles over glyphosate continue, the public must grapple with the reality that regulatory actions can be significantly influenced by corporate interests. This incident serves as a stark reminder of the need for vigilance in protecting public health from potential corporate overreach. It highlights the imperative for regulatory bodies to prioritise the safety and well-being of the community over the profits of major corporations. The outcome of this case may not only determine Bayer’s financial future but could also set a precedent affecting environmental regulation and public health for years to come.
